Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

<jats:title>Abstract</jats:title><jats:sec><jats:title>Background</jats:title><jats:p>The Platform Randomised trial of INterventions against COVID-19 In older peoPLE (PRINCIPLE) trial has provided in-pandemic evidence of what does not work in the early primary care management of coronavirus-2019 disease (COVID-19). PRINCIPLE’s first finding was that azithromycin and doxycycline were not effective.</jats:p></jats:sec><jats:sec><jats:title>Aim</jats:title><jats:p>To explore the extent to which azithromycin and doxycycline were being used in-pandemic, and the scope for trial findings impacting on practice.</jats:p></jats:sec><jats:sec><jats:title>Design and Setting</jats:title><jats:p>We compared crude rates of prescribing and respiratory tract infections (RTI) in 2020, the pandemic year, with 2019, using the Oxford-Royal College of General Practitioners (RCGP) Research and Surveillance Centre (RSC).</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>We used a negative binomial model including age-band, gender, socioeconomic status, and NHS region to compare azithromycin and doxycycline lower respiratory tract infections (LRTI), upper respiratory tract infections (URTI), and influenza-like-illness (ILI) in 2020 with 2019; reporting incident rate ratios (IRR) between years and 95% confidence intervals (95%CI).</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>Azithromycin prescriptions increased 7% in 2020 compared to 2019, whereas doxycycline decreased by 7%. Concurrently, LRTI and URTI incidence fell by over half (58.3% and 54.4% respectively) while ILI rose slightly (6.4%). The overall percentage of RTI prescribed azithromycin rose by 42.1% between 2019 and 2020, doxycycline increased by 33%.</jats:p><jats:p>Our adjusted IRR showed azithromycin prescribing was 22% higher in 2020 (IRR=1.22, 95%CI:1.19-1.26, p&lt;0.0001), for every unit rise in confirmed COVID there was an associated 3% rise in prescription (IRR=1.026, 95%CI 1.024-1.0285, p&lt;0.0001); whereas these measures were static for doxycycline.</jats:p></jats:sec><jats:sec><jats:title>Conclusion</jats:title><jats:p>PRINCIPLE trial flags scope for improvement in antimicrobial stewardship.</jats:p></jats:sec>

Original publication




Journal article


Cold Spring Harbor Laboratory

Publication Date